Drug intelligence / Profile preview

normal saline + standard treatment

Development stage: Unknown
Lead developer: Pharmazz
Modality: Small Molecules
Administration: Intravenous

Overview

Normal saline + standard treatment refers to the control arm regimen used in clinical trials sponsored by Pharmazz, Inc., specifically for the treatment of hypovolemic shock. In the Phase III trial (NCT04045327), this arm serves as the comparator to the experimental resuscitative agent centhaquine (PMZ-2010). Normal saline (0.9% sodium chloride solution) acts as an isotonic crystalloid for volume expansion and as a vehicle for blinding, while "standard treatment" encompasses the standard of care for shock resuscitation, which may include intravenous fluids, blood products, and vasopressors according to established medical guidelines.

Other names: Control ArmVehicle + Standard Treatment

Beyond the preview

Go deeper on normal saline + standard treatment.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on normal saline + standard treatment.

Explore the full profile